NCT05518201 2024-04-17
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
Clinical Trials
8 trialsNCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT02405520 2022-05-24
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Xiamen University
Phase 1 Completed
NCT03813940 2021-04-08
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 1 Completed
NCT00851643 2016-02-03
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01490008 2012-04-19
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
MediGene
Phase 1 Completed
NCT00002327 2005-06-24
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
NIH AIDS Clinical Trials Information Service
Phase 1 Completed